An observational study in Heart Diseases, Heart Failure and Heart Defects, Congenital, sponsored by Paragonix Technologies. Enrolling by invitation at 22 sites in 4 countries. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Paragonix Technologies · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 646 studies in Heart Diseases with a site in United States — 92 open to participants now, 131 under way, 5 of them phase 3. Heart Diseases · United States.
Among the 646 studies in Heart Diseases with a site in United States, this one is the 30th largest by planned enrollment of the 206 observational ones that give a count, is one of 29 that started in 2020, is one of 211 observational ones, reaches primary completion later than 91 of the 128 other live ones, and was the 476th registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →92 of the 646 studies in Heart Diseases with a site in United States are open now. Recruiting first, the newest first:
Barbara Ann Karmanos Cancer Institute · Sites in United States
Ages 18+
AnaCardio AB · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–85
Abiomed Inc. · Sites in United States
Ages 18–80
Edwards Lifesciences · Sites in United States
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
646 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 62 · Phase 3 71 · Phase 4 36
First in 1973; this study’s year is marked. 29 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,000 is above the median of 350 across 592 observational studies indexed under Heart Diseases.
Median enrollment 161 across the 430 interventional studies, 300 across the 206 observational. Of the 469 that completed or were terminated, 158 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 646 have an industry lead sponsor. The 10 most frequent:
Paragonix Technologies is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Paragonix Technologies has 1 study filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
40 of the studies in Heart Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT05153967Vanderbilt University Medical CenterCooperative Assessment of Late Effects for SCD Curative Therapies | 2026-11 |
| NCT06891222Mayo ClinicA Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening | 2026-11 |
| NCT06703489Medtronic Cardiac Ablation SolutionsSafety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | 2026-11 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 646 studies in Heart Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving heart transplants using donor hearts transported via the SherpaPak CTS System. These results will be compared to outcomes of retrospective patients whose hearts were transported with the previous standard method.
CONCERT DCD is a substudy designed to assess the safety and feasibility of a direct procurement method for donation after circulatory death (DCD) heart procurement (CONCERT DCD) that utilizes preservation in a SherpaPak Cardiac Transport System. This DCD Substudy will be limited to approved GUARDIAN-Heart Registry sites who have been qualified to participate. The DCD Substudy will include prospective recipient identification and documentation of informed consent.
This study is a registry study collecting data both retrospectively from patients already transplanted and prospectively from consecutively enrolled patients for heart transplantation. The study is a chart review study.
Ongoing eligible recipients will undergo heart transplantation according to standard practices at each participating institution.
This study will be conducted at an estimated 25 institutions globally and will have about up to 3000 patients. Subjects will be followed from transplant through one-year post-transplantation (i.e., 24 hours post-transplant, discharge, 30-days, 1-year, 2-years, 3-years, 4-years, 5-years).
GUARDIAN provides critical and contemporary data on patient outcomes, with additional insight into risk factors and patient-related indices. Both donor and recipient information along with procedural details (including transportation) will be collected to provide information for major discrete endpoints such as death, primary graft dysfunction, right ventricular dysfunction, CPB weaning, Inotrope use, CAV diagnosis, rejection, and survival.
Information about re-hospitalizations and re-transplantations is vital to address the integrated endpoint of days alive out of hospital, which is particularly relevant for this patient population. In addition, the number of in-hospital days and ICU time is closely tracked as the major resource utilized, after the initial transplant.
CONCERT DCD Substudy:
CONCERT DCD, Cold Oxygenated Flush, No reanimation, Controlled Preservation Technique for DCD , is a cold oxygenated non-reanimation perfusion method using blood, bicarbonate and Wisconsin (UW) Preservation Solution. Hearts are procured following a cold, buffered blood flush (150 mL/min for approximately 20 minutes), followed by arrest with standard UW preservative. This utilizes a simplified perfusion circuit consisting of a centrifugal pump, reservoir, oxygenator, and heater/cooler. The same datapoints will be collected for this study. In addition to the Donor and Recipient inclusion criteria in the overall GUARDIAN heart registry, the following additional criteria will be required in the CONCERT DCD Substudy:
Recipient: Status 1 or 2
Recipients with Congenital heart etiologies will be excluded.
Donors: Aged 16-40
Anticipated total ischemic time (cross clamp time) \<5 hours
Echo-confirmed functionally normal heart
No prior coronary disease, including significant valvular or ventricular dysfunction
Patients registered on the heart transplant registry who receive a heart transplant at a participating center and do not meet any of the exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients whose donor heart was transported with the SherpaPak CTS
Device: SherpaPak Cardiac Transport System
Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years
Patients whose DCD heart was procured using a cold oxygenated flush with no reanimation and then transported in the SherpaPak CTS
The Paragonix SherpaPak Cardiac Transport System ("SherpaPak CTS") is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union. The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached.
Also known as: SherpaPak CTS
Number of Patients with Primary Graft Dysfunction
Less than 40% LVEF by echocardiography or hemodynamics with RAP greater than 15 mm Hg, PCWP greater than 20 mm Hg, CI less thann 2 L/min/m\^2, hypotension with MAP less than 70 mm Hg (lasting more than 1 hour)
Time frame: one year
Number of Patients with Right Ventricular Dysfunction
hemodynamics with RAP grater than 15mm Hg, PCWP less than 15 mm Hg, CI less than 2 L/min/m\^2, TPG less than 15mm Hg/pulmonary artery systolic pressure less than 50 mmHg OR need for RVAD
Time frame: one year
Length of ICU Stay
Length of time patient admitted to the intensive care unit post transplant
Time frame: one year
Length of Hospital Stay
Length of time before patient is discharged from the hospital post transplant
Time frame: one year
Survival
The length of patient survival up to 5 years will be compared
Time frame: 5 years
Hospitalizations
Number of related hospitalizations post transplant
Time frame: one year
CAV development
Number of patients who developed CAV between 1 and 5 years post transplant will be compared
Time frame: five years
Retransplant
The number of patients who were retransplanted will be compared
Time frame: five years
Plan to share: No — Data will only be released as a summary of the results found at each center and overall. No individual patient data will be released.
Started Feb 2020 (actual). Primary completion is estimated for Dec 2028, 106 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Dec 2028, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Paragonix Technologies